Plain-English translation of NCT03689595 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →The PROMISE study is looking for early warning signs of multiple myeloma—a blood cancer—in people who are at higher risk because of their family history or ancestry. Researchers will analyze blood samples to find genetic and other changes that might predict whether someone will develop this disease in the future. This information could help doctors catch the disease earlier or find new ways to prevent it.
Multiple myeloma often develops from earlier conditions that can be detected before symptoms appear. By studying blood samples from high-risk people now, researchers hope to understand which changes predict progression to the full disease, so doctors can intervene sooner.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have one visit where researchers will collect a blood sample (about 2 to 4 tablespoons) using standard blood tubes. The blood will then be analyzed in the laboratory to look for genetic changes and other markers that might indicate risk for developing multiple myeloma. This is a non-invasive screening study with no ongoing treatment involved.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States
Enrollment target
~30,000 participants
Started
October 2018
Primary completion
October 2033
Age range
30 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.